Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Blockade of the CX3CL1-CX3CR1 Pathway Inhibits the Progress of Skin Inflammation, Fibrosis, and Vascular Injury in an Experimental Mouse Model of Systemic Sclerosis.

Luong VH, Utsunomiya A, Chino T, Le DH, Matsushita T, Obara T, Kuboi Y, Ishii N, Machinaga A, Ogasawara H, Ikeda W, Kawano T, Imai T, Oyama N, Hasegawa M.

Arthritis Rheumatol. 2019 Jun 7. doi: 10.1002/art.41009. [Epub ahead of print]

PMID:
31173491
2.

Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time.

Motoi S, Toyoda H, Obara T, Ohta E, Arita Y, Negishi K, Moriya K, Kuboi Y, Soejima M, Imai T, Ido A, Tsubouchi H, Kawano T.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1821. doi: 10.3390/ijms20081821.

3.

Blockade of the fractalkine-CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes.

Kuboi Y, Nishimura M, Ikeda W, Nakatani T, Seki Y, Yamaura Y, Ogawa K, Hamaguchi A, Muramoto K, Mizuno K, Ogasawara H, Yamauchi T, Yasuda N, Onodera H, Imai T.

Int Immunol. 2019 Apr 26;31(5):357. doi: 10.1093/intimm/dxz035. No abstract available.

PMID:
31002334
4.

Blockade of the fractalkine-CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes.

Kuboi Y, Nishimura M, Ikeda W, Nakatani T, Seki Y, Yamaura Y, Ogawa K, Hamaguchi A, Muramoto K, Mizuno K, Ogasawara H, Yamauchi T, Yasuda N, Onodera H, Imai T.

Int Immunol. 2019 Apr 26;31(5):287-302. doi: 10.1093/intimm/dxz006.

PMID:
30668715
5.

Role of Anti-Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis.

Hoshino-Negishi K, Ohkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y, Kakuta J, Hamaguchi A, Kumai M, Kamisako T, Sugiyama F, Ikeda W, Ishii N, Yasuda N, Imai T.

Arthritis Rheumatol. 2019 Feb;71(2):222-231. doi: 10.1002/art.40688.

PMID:
30079992
6.

Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease.

Ohkuro M, Kim JD, Kuboi Y, Hayashi Y, Mizukami H, Kobayashi-Kuramochi H, Muramoto K, Shirato M, Michikawa-Tanaka F, Moriya J, Kozaki T, Takase K, Chiba K, Agarwala KL, Kimura T, Kotake M, Kawahara T, Yoneda N, Hirota S, Azuma H, Ozasa-Komura N, Ohashi Y, Muratani M, Kimura K, Hishinuma I, Fukamizu A.

Nat Commun. 2018 May 17;9(1):1982. doi: 10.1038/s41467-018-04420-4.

7.

E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis.

Wakita H, Yanagawa T, Kuboi Y, Imai T.

Mol Pharmacol. 2017 Nov;92(5):502-509. doi: 10.1124/mol.117.108381. Epub 2017 Aug 25.

PMID:
28842393
8.

E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration.

Muramoto K, Goto M, Inoue Y, Ishii N, Chiba K, Kuboi Y, Omae T, Wang YJ, Gusovsky F, Shirota H.

J Pharmacol Exp Ther. 2010 Oct;335(1):23-31. doi: 10.1124/jpet.110.168583. Epub 2010 Jul 13.

PMID:
20627998
9.

Chemokines as novel therapeutic targets for inflammatory bowel disease.

Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T.

Ann N Y Acad Sci. 2009 Sep;1173:350-6. doi: 10.1111/j.1749-6632.2009.04738.x. Review.

PMID:
19758172

Supplemental Content

Loading ...
Support Center